Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Whether and when systemic lupus erythematosus (SLE) patients with stable disease should
withdraw glucocorticoid (GC)? How about the relapse risk? What are the risk factors for
disease flare? All the above are unclear. Long-course GC treatment has a lot of side-effects
even in a sustaining low dose. The aim of this study is to explore the relapse risk after GC
withdrawal in SLE patients with stable disease more than one year and to establish a
predictive model for flare risk stratification.
Phase:
N/A
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Anhui Provincial Hospital People's Hospital of Xinjiang Uygur Autonomous Region Shengjing Hospital Xiangya Hospital of Central South University